Sprout
OrganizationRelationship Network
| Connected Entity | Relationship Type |
Strength
(mentions)
|
Documents | Actions |
|---|---|---|---|---|
|
organization
New Leaf
|
Business associate |
8
Strong
|
3 | |
|
person
Craig L. Slutzkin
|
Former employment |
6
|
1 | |
|
organization
Sprout
|
Affiliation assistance |
5
|
1 | |
|
organization
New Leaf
|
Fund management |
5
|
1 | |
|
person
Fund Managers
|
Management |
5
|
1 | |
|
person
New Leaf team
|
Financial |
5
|
1 | |
|
organization
New Leaf
|
Co managed |
5
|
1 | |
|
person
New Leaf team
|
Management historical affiliation |
5
|
1 | |
|
organization
CIA
|
Data provider benchmark |
5
|
1 | |
|
organization
Credit Suisse First Boston
|
Affiliate |
1
|
1 | |
|
person
Philippe Chambon
|
Employee |
1
|
1 | |
|
organization
New Leaf
|
Service provider |
1
|
1 | |
|
person
New Leaf (NLV)
|
Historical predecessor |
1
|
1 |
| Date | Event Type | Description | Location | Actions |
|---|---|---|---|---|
| N/A | N/A | Spin-out of New Leaf from Sprout. | Unknown | View |
HOUSE_OVERSIGHT_024050.jpg
This document is page 39 of a confidential investment memorandum or fund report stamped by House Oversight. It details specific healthcare investment themes including Care Coordination, Clinical Error Reduction, and Analytics/Data-Driven Personalization, highlighting portfolio companies such as TigerText, ePocrates, iRhythm Technologies, and Treato. The document notes the financial success of ePocrates (acquired for $293 million) and attributes several companies to a fund designated as 'NLV-II'.
HOUSE_OVERSIGHT_024046.jpg
This document appears to be page 35 of a confidential investment memorandum for a fund named NLV-III (likely New Leaf Venture Partners). It outlines the fund's track record with previous investments (NLV-II) in companies like Array, Acadia, and Intercept Pharmaceuticals, highlighting successful exit multiples. The text details the investment thesis for NLV-III, focusing on targeted biopharmaceutical therapies and biomarker-guided programs that benefit patients, physicians, payers, and pharmaceutical companies. The document bears a House Oversight Committee stamp.
HOUSE_OVERSIGHT_024045.jpg
This document is a confidential investment report page (marked House Oversight) detailing the track record of New Leaf Ventures (NLV) in the biopharmaceutical sector. It highlights their investment strategy, networking capabilities, and specific performance metrics (multiples on invested capital) for various portfolio companies across funds NLV-I, NLV-II, and Sprout Funds. The text lists specific exits and IPOs occurring between 2011 and 2013.
HOUSE_OVERSIGHT_024034.jpg
This document is page 23 of a confidential financial report (Control Number 257) marked with a House Oversight Bates stamp. It details the investment performance of New Leaf Ventures (I and II) and Sprout Funds in two sectors: Medical Devices and Tools, Diagnostics, & Infrastructure, as of March 31, 2014. The report lists aggregate costs, realized values, and internal rates of return (IRR) for these funds.
HOUSE_OVERSIGHT_024033.jpg
This document is a confidential financial report summarizing the investment performance of New Leaf Ventures and Sprout Funds by sector as of March 31, 2014. It details performance metrics (Gross Value, Multiple, and IRR) for Biopharmaceutical and Information Convergence investments across multiple funds dating back to 1993. The document carries a House Oversight Committee stamp, indicating it was part of a congressional investigation.
HOUSE_OVERSIGHT_024032.jpg
This document is a confidential financial chart titled 'Returns by Fund' as of March 31, 2014, bearing a House Oversight stamp. It details the performance metrics (IRR, Multiples, Capital) for six funds: Growth II HCT, Sprout VII HCT, Sprout VIII HCT, Sprout IX HCT, NLV-I, and NLV-II. The chart compares these funds against public indices like the S&P 500 and Nasdaq, showing significant distributed capital totaling over $1 billion for the largest fund listed.
HOUSE_OVERSIGHT_024029.jpg
This document is page 18 of a confidential report, likely a Private Placement Memorandum or due diligence report, bearing a House Oversight Committee stamp. It details the historical investment performance of the 'New Leaf team' (associated with NLV-I and NLV-II funds) and their previous management of 'Sprout Capital' funds. The text highlights a track record of investing over $1.67 billion in healthcare technology since 1995, generating over $2.6 billion in gross realizations and outperforming major financial indices like the S&P 500 and NASDAQ.
HOUSE_OVERSIGHT_024026.jpg
This document is page 15 of a confidential corporate report or prospectus for an entity named "New Leaf" (likely New Leaf Venture Partners). It profiles Craig L. Slutzkin, the Chief Financial Officer, detailing his background at Sprout, Arthur Andersen, and Ernst & Young. The document also outlines the firm's strategy regarding Industry Advisors, specifically noting they use a broad network for Therapeutics rather than a formal board, while maintaining a specific advisory board for Information Convergence. The document bears a House Oversight stamp.
HOUSE_OVERSIGHT_024025.jpg
This document is a confidential page (Control Number 257) marked with 'HOUSE_OVERSIGHT', detailing the professional biographies of five investment professionals (Kathy LaPorte, Mark Charest, Mike Dybbs, Eric Kim, and Isaac Manke) working for a firm called 'New Leaf' (New Leaf Venture Partners). The document establishes the educational and professional backgrounds of these individuals, including previous employment at major firms like Deutsche Bank, McKinsey, and BCG. The most recent date mentioned in the text is December 2013.
HOUSE_OVERSIGHT_024024.jpg
This document (page 13, Control Number 257) contains professional biographies for James Niedel and Liam Ratcliffe, executives at New Leaf Venture Partners. It details their educational backgrounds, board memberships, and extensive history in the pharmaceutical industry (GSK and Pfizer respectively), including specific successful drug developments and corporate acquisitions. The document is marked confidential and bears a House Oversight file stamp.
HOUSE_OVERSIGHT_024023.jpg
This document is a page from a corporate prospectus or due diligence report (marked Confidential, House Oversight) detailing the professional biographies of three Managing Directors at New Leaf (presumably New Leaf Venture Partners): Jeani Delagardelle, Ron Hunt, and Vijay Lathi. All three were previously associated with Sprout Group. The document lists their educational backgrounds and extensive board memberships across various pharmaceutical and medical technology companies.
HOUSE_OVERSIGHT_024022.jpg
This document is page 11 of a confidential presentation (likely an investment prospectus for 'NLV-III') detailing the history and senior team of New Leaf Ventures. It features a timeline of funds raised from 1993 to 2007 under Sprout and New Leaf brands, totaling billions in capital. The page highlights the biography of Managing Director Philippe Chambon, detailing his history with Sprout, Boston Consulting Group, and Sandoz Pharmaceutical, as well as his numerous board memberships in the healthcare and biotech sectors. The document bears a House Oversight Committee control number.
HOUSE_OVERSIGHT_024014.jpg
A confidential financial document, bearing a House Oversight Committee stamp, detailing the historical investment performance of 'New Leaf' and 'Sprout Capital' funds as of March 31, 2014. The document presents a chart comparing fund returns against public indices like the S&P 500 and NASDAQ, highlighting that New Leaf team members invested over $1 billion in Sprout Capital healthcare portfolios with significant returns. The page serves as evidence of financial tracking, likely part of a broader investigation into financial networks.
HOUSE_OVERSIGHT_024013.jpg
This document appears to be page 2 of a confidential investment memorandum or prospectus for 'New Leaf' (NLV) funds, specifically discussing the transition of Jim Niedel to Venture Partner for the NLV-III fund. It highlights the 'Long Term Track Record' of the fund managers, noting they have invested over $1.6 billion since 1995 through NLV and Sprout Capital funds, consistently outperforming benchmarks like Cambridge Associates. The document bears a House Oversight Committee stamp, suggesting it was part of a congressional investigation.
HOUSE_OVERSIGHT_024012.jpg
This document is an Executive Summary for 'New Leaf Ventures III, L.P.' (NLV-III), a healthcare technology investment fund targeting $375 million in capital commitments. It details the history of the management company, New Leaf Venture Partners, outlining previous funds (NLV-I and NLV-II) and their affiliation with Sprout Group/Credit Suisse. The document lists the Managing Directors and outlines the fund's strategy to invest in 24-28 U.S.-based healthcare companies. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a congressional document production.
HOUSE_OVERSIGHT_024011.jpg
This document is a Table of Contents for a confidential investment memorandum or offering document related to New Leaf Venture Partners and the healthcare sector. It outlines sections regarding historical performance, investment strategy, and an ongoing relationship with Sprout Funds. The page bears a House Oversight Bates stamp, indicating it is part of a congressional investigation.
HOUSE_OVERSIGHT_024009.jpg
This page contains legal disclaimers for a confidential investment memorandum, likely regarding New Leaf Ventures funds (I, II, and III). It includes standard warnings regarding forward-looking statements, tax liabilities (IRS Circular 230), and investment risks. The document explicitly states that the information is current as of March 31, 2014, and clarifies that Credit Suisse has no affiliation with the funds mentioned and did not prepare the memorandum.
HOUSE_OVERSIGHT_024109.jpg
This document page contains footnotes (C through G) for a financial report, detailing the methodology used to calculate investment returns (IRR, DPI) for 'Sprout Funds' and funds identified as 'NLV-I' and 'NLV-II'. It establishes a valuation date of March 31, 2014, defines healthcare technology sectors, and references data provided by Cambridge Associates for benchmarking. The document bears a House Oversight Committee Bates stamp.
HOUSE_OVERSIGHT_024108.jpg
This document is Appendix 5 (Endnotes) of a confidential financial report dated as of March 31, 2014, obtained by the House Oversight Committee (Bates stamp HOUSE_OVERSIGHT_024108). It outlines the methodology for financial performance reporting for funds identified as NLV-I, NLV-II, and the Sprout Funds, distinguishing between 'gross' and 'net' performance and providing legal disclaimers regarding valuations and future results. The document defines the roles of generic 'Fund Managers' and the 'Sprout Group' in managing these investments.
HOUSE_OVERSIGHT_024106.jpg
This document outlines the methodology used by New Leaf to calculate synthetic net returns for Sprout Healthcare Technology Portfolios. It explains the assumption of a standalone fund structure and provides a specific financial breakdown for 'Sprout IX,' detailing investments ($740M), fees ($120M), carried interest ($130M), and distributions to Limited Partners ($1,075M). The document bears a House Oversight Committee Bates stamp.
HOUSE_OVERSIGHT_024105.jpg
This document is 'Appendix 2' of a confidential report (Control Number 257) associated with a House Oversight investigation (HOUSE_OVERSIGHT_024105). It provides a financial summary table titled 'All Funds Gross and Net Returns' as of March 31, 2014. The table details the performance of several investment funds, specifically New Leaf Ventures (I and II) and several Sprout Capital/Growth funds, listing metrics such as Total Cost, Realized/Unrealized values, Fund Size, and Internal Rate of Return (IRR).
HOUSE_OVERSIGHT_024104.jpg
This document is a confidential financial schedule detailing the 'Healthcare Technology Portfolio' performance for two funds: Sprout Capital VII, L.P. and Sprout Growth II, L.P., as of March 31, 2014. It lists specific portfolio companies (such as WebMD, Cephalon, and Adeza Biomedical), the vintage year of investment (ranging 1994-2003), investment costs, realized values, and Internal Rates of Return (IRR). The document bears a House Oversight Bates stamp (HOUSE_OVERSIGHT_024104), indicating it was part of a congressional investigation, likely related to financial probes involving entities connected to the broader Epstein investigation.
HOUSE_OVERSIGHT_024103.jpg
This document is a financial appendix page (marked CONFIDENTIAL) bearing a House Oversight Bates stamp (HOUSE_OVERSIGHT_024103). It details the investment performance of 'Sprout Capital VIII, L.P. (Healthcare Technology Portfolio)' as of March 31, 2014. It lists specific investments in healthcare and technology companies (such as Charles River Laboratories and eHealth, Inc.), showing the vintage year (ranging from 1998-2000), total cost, realized value, and internal rate of return (IRR) for each.
HOUSE_OVERSIGHT_024102.jpg
This document is a confidential financial schedule for 'Sprout Capital IX, L.P. (Healthcare Technology Portfolio)' as of March 31, 2014. It details realized and unrealized investments in numerous healthcare and biotechnology companies, listing vintage years, costs, realized values, and IRRs. The document bears a 'HOUSE_OVERSIGHT' footer, indicating it was part of a congressional investigation.
HOUSE_OVERSIGHT_024074.jpg
This document appears to be page 63 of a confidential Private Placement Memorandum or Offering Memorandum describing risk factors for an investment fund. It details the lack of control Limited Partners have over management, reliance on the General Partner and Fund Managers, and potential conflicts of interest arising from the managers' involvement with other entities like 'Sprout Funds,' 'NLV-I,' and 'NLV-II.' The document bears a House Oversight control number, suggesting it was produced during a congressional investigation.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity